CDER Eyes Prioritization, Timely Resolution Of Post-Marketing Safety Issues
Now that it has a system in place to track post-marketing drug safety issues, FDA’s Center for Drug Evaluation and Research is turning its attention to setting standard timeframes for investigating and addressing such signals.
You may also be interested in...
REMS Templates Get Nod From FDA, With Nudge From Pharmacists
At workshop, agency acknowledges efficiency and implementation burdens that the myriad risk management program programs create, but developing a standardized approach will not easy task either.
PhRMA Wants MedGuides Developed The Pre-FDAAA Way, Not Through REMS
Using 1998 authority would reduce the burden on sponsors, physicians and patients, industry group says.
FDA Seeks To Write MedGuides Outside REMS Process
FDA is searching for a way out of imposing a REMS when only a medication guide is required